Erratum: Effect of Ofloxacin and Norfloxacin on Rifampicin Pharmacokinetics in Man (American Journal of Therapeutics (2015) 22 (29-36) DOI: 10.1097/MJT.0b013e31826fc1ba);Effect of ofloxacin and norfloxacin on rifampicin pharmacokinetics in man

American Journal of Therapeutics

Volumn 22, Issue 1, 2015, Pages 29-36

  Ezejiofor, Ndidi A ^a   Brown, Sinyeofori ^a   Barikpoar, Ebenezer ^a   Orisakwe, Orish E ^a  

^a UNIVERSITY OF PORT HARCOURT   (Nigeria)

Author keywords

Fluoroquinolones; plasma; rifampicin; saliva and urine pharmacokinetics

Indexed keywords

NORFLOXACIN; OFLOXACIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SALIVA ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VOLUME OF DISTRIBUTION; ADOLESCENT; BIOAVAILABILITY; CHEMISTRY; DRUG INTERACTION; DRUG MONITORING; ORAL DRUG ADMINISTRATION; PROCEDURES; SALIVA; TIME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; NORFLOXACIN; OFLOXACIN; RIFAMPIN; SALIVA; TIME FACTORS; YOUNG ADULT;

EID: 84921438379     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000819     Document Type: Erratum

References (30)

1. Mandell GL, Petri WA. Drug used in chemotherapy of tuberculosis Mycobacterium avium complex disease and leprosy. In: Gilman G, ed. McGraw-Hill Professional, New York. Principles of Therapeutics. 1998:1155-1174.
2. Schranfnagel DE. TB treatment for the beginning of the next century. Int J Tuberc Lung Dis. 1999;3:651-662.
3. Daniel TM. Evidence of tuberculosis in Uganda (East Africa). Int J Tuberc Lung Dis. 1998;2:784-790.
4. Ji B, Lefrancois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother. 2006;50:1921-1926.
5. Ji B, Chauffour A, Robert J, et al. Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2007; 51:3737-3739.
6. World Health Organization. Global Leprosy Situation. Weekly Epidemiological Record. 2010. Available at: http://www.who.int/wer/2010/wer8535.pdf. Accessed October 19, 2010.
7. World Health Organization. WHO Multidrug Therapy (MDT). 2010. Available at: http://www.who.int/lep/mdt/en/. Accessed May 2, 2012.
8. Gautam VP. Treatment of leprosy in India. J Postgrad Med. 2009;55:220-224.
9. World Health Organization. Tropical medicine and international health. 2011;16:1541-1551. doi:10.1111/j.1365-3156.2011.02873.x.
10. World Health Organization. Chemotherapy of Leprosy for Control Programmes (No. 675). World Health Organization; 1982. http://whqlibdoc.who.int/trs/WHO-TRS-675.pdf. Accessed May 15, 2012.
11. Sehgal VN, Sardana K, Dogra S. The imperatives of leprosy treatment in the pre-and post-global leprosy elimination era: appraisal of changing the scenario to current status. J Dermatolog Treat. 2008;19:82-91.
12. World Health Organization. WHO Model Prescribing Information: Drugs Used in Leprosy. Geneva, Switzerland: World Health Organization; 1998.
13. Setia MS, Shinde SS, Jerajani HR, et al. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and metaanalysis. Trop Med Int Health. 2011;16:1541-1551. doi:10. 1111/j.1365-3156.2011.02873.x.
14. Meima A, Smith WC, van Oortmarssen GJ, et al. The future incidence of leprosy: a scenarioanalysis. Bull World Health Organ. 2004;82:373-380.
15. World Health Organization. The Global Tuberculosis Control. Geneva, Switzerland: World Health Organization; 2009.
16. Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis. 2008;8:10.
17. Barbassa L, Mamizuka EM, Carmona-Ribeiro AM. Supramolecular assemblies of rifampicin and cationic bilayers: preparation, characterization and mycobactericidal activity. BMC Biotechnol. 2011;11:40. http://www.biomedcentral. com/1472-6750/11/40. Accessed May 15, 2012.
18. Lettieri JT, Rogge MC, Kaiser L, et al. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992;36: 993-996.
19. O'Brien DP, McDonald A, Callan P, et al. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis. 2012;6: e1473. doi:10.1371/journal.pntd.0001473.
20. Bradley JS, Jackson MA; The Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones [published online September 26, 2011]. Pediatrics. 2011;128:e1034. http://pediatrics.aappublications.org/content/128/4/e1034.full.html.
21. Sunahara S, Nakagawa H. Metabolic study and clinical trials of rifampicin. Chest. 1972;61:526-529.
22. Wagner JG. Fundamentals of Clinical Pharmacokinetics. Hamilton, IL: Drug Intelligence Publication III; 1975:63.
23. Gibaldi M, Perrie D. Pharmacokinetics. New York, NY: Marcel Decker; 1975.
24. Ritschel WA. Handbook of Basic Pharmacokinetics. 2nd ed. Drug Intelligence Publications, Hamilton, IL. 16617.
25. Orisakwe OE, Ofoefule SS. Plasma and saliva concentration of rifampicin in man after oral administration. Tokai J Exp Clin Med. 1996;2:45-49.
26. Labaune JP. Handbook of Pharmacokinetics. Chichester, United Kingdom: Ellis Harwood Limited; 1989:135-138.
27. Jaruratanasirikul S, Sriwiriyajan S. Effects of rifampicin on the pharmacokinetic of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol. 1998;54;155-158.
28. Ofoefule SI, Obodo CE, Orisakwe OE, et al. Some plasma pharmacokinetics parameters of isoniazide (INH) in the presence of a fluoroquinolones anti-bacterial agent. Am J Ther. 2004;8:243-246.
29. Louw GE, Warren RM, Gey van Pittius NC, et al. Rifampicin reduces susceptibility to ofloxacin in rifampicin resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med. 2011;186:953-964.
30. Orisakwe OE, Agbasi PU, Ofoefule SI, et al. Effect of perfloxacin on urinary excretion of rifampicin. Am J Ther. 2004;11:13-16.